Bronchitis News and Research

RSS

Bronchitis is a condition in which the bronchial tubes, the tubes that carry air to your lungs, become inflamed. (For more information on the bronchial tubes and the airways. People who have bronchitis often have a cough that brings up mucus. Mucus is a slimy substance made by the lining of the bronchial tubes. Bronchitis also may cause wheezing (a whistling or squeaky sound when you breathe), chest pain or discomfort, a low fever, and shortness of breath. There are two main types of bronchitis: acute (short term) and chronic (ongoing).

Empire BlueCross BlueShield introduces Medicare Advantage plans in New York City

Empire BlueCross BlueShield is introducing a number of Medicare Advantage (MA) plans in New York City that include access to the acclaimed CareMore health delivery system, which helps members maintain their health.

15 Oct 2012

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Merck, known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women.

15 Oct 2012

Safety tips to avoid common farm injuries

The hectic fall harvest is under way, and that means the dangers of everyday farm work -- one of the nation's most hazardous occupations -- are compounded by the rush to bring in crops on time. Many agricultural injuries can be prevented with basic safety equipment and mindfulness about the need for caution on the job, says emergency medicine physician Howard Schumaker, M.D., of the Mayo Clinic Health System in Sparta.

11 Oct 2012

Positive results from Noven’s LDMP Phase 3 clinical studies on menopausal VMS

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced positive results from two multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical studies evaluating low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

3 Oct 2012

Japanese MHLW approves Sosei’s Seebri inhalation capsules to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg administered through the Breezhaler device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease.

28 Sep 2012

Patients with chronic obstructive pulmonary disease experience poor sleep quality

Patients with chronic obstructive pulmonary disease (COPD) experience poorer sleep quality than people of a similar age without COPD, according to research published in the journal Respirology.

21 Sep 2012

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

17 Sep 2012

CT shows promise in predicting COPD exacerbation risk

Measurement of the pulmonary artery-to-aorta ratio can predict the risk for exacerbations in patients with chronic obstructive pulmonary disease, particularly those that require hospitalization, say the authors of a US study.

11 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Boehringer Ingelheim announces data from olodaterol plus tiotropium Phase II COPD study

Boehringer Ingelheim presented today for the first time data from a Phase II dose ranging study investigationg the combination of olodaterol, an investigational long-acting beta2-agonist (LABA), and tiotropium, a long-acting muscarinic antagonist (LAMA), in COPD patients, compared to the investigational agent olodaterol alone.

3 Sep 2012

Positive results from Elevation Pharmaceuticals’ EP-101 Phase 2b study on COPD

Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study – a Phase 2b study evaluating EP-101 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) – at the annual meeting of the European Respiratory Society in Vienna, Austria.

3 Sep 2012

Potential new COPD drug

A study led by researchers at Boston University School of Medicine (BUSM) has shown that a compound used in some skin creams may halt the progression of emphysema and reverse some of the damage caused by the disease. When the compound Gly-His-Lys (GHK) was applied to lung cells from patients with emphysema, normal gene activity in altered cells was restored and damaged aspects of cellular function were repaired.

1 Sep 2012

Specialist referral unearths wide spectrum of adult primary immune deficiencies

The range of adult primary immune deficiencies is considerable and the majority of patients are diagnosed only after specialist referral, conclude Canadian scientists who identified two novel patient groups with humoral abnormalities.

20 Aug 2012

Secondhand smoke exposure decreases sensitivity to cough-eliciting respiratory irritants in children

New research from the Monell Center reveals that exposure to secondhand smoke decreases sensitivity to cough-eliciting respiratory irritants in otherwise healthy children and adolescents.

20 Aug 2012

Study to test how osteopathic treatment helps patients with COPD

Researchers at Michigan State University are working to show how a noninvasive, drug-free form of hands-on medical care can help patients with chronic obstructive pulmonary disease improve their breathing.

15 Aug 2012

Tai Chi improves health and quality of life for COPD sufferers

A new University of Sydney study has found Tai Chi can be an effective form of exercise therapy for people with chronic obstructive pulmonary disease (COPD), improving exercise capacity and quality of life.

14 Aug 2012

Hypoxic lung environment increases HIF-2a tumor growth signaling

In addition to the well-known risk factor of smoking, chronic obstructive pulmonary disease (COPD) increases lung cancer risk.

25 Jul 2012

FDA approves Forest Laboratories’ Tudorza Pressair to treat COPD

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Tudorza Pressair (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Forest Pharmaceuticals receives FDA approval for Tudorza Pressair to treat COPD

The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Nicotine addiction: An interview with Dr. Crystal

Cigarette smoking and nicotine addiction are widespread problems throughout the world. Many people continue to smoke despite high taxes and the available public information on the dangers of smoking.

3 Jul 2012